NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

NeoGenomics, Inc.NASDAQ: NEO

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin dips below year-ago levels

Q2 FY2026 selling, general & admin of $90.89M fell 5.1% year over year, behind the +0.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.

Context

  • Selling, general & admin amounted to 50.2% of revenue in FY2025, up 3.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $416.54M (+14.0%) for the fiscal year ending Dec 2026, a slowdown from the +17.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$90.89M+1.5% QoQ
Last fiscal yearDec 2025
$365.34M+17.7% YoY
LTMJun 2026
$359.09M+0.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.1%+16.2%+21.4 pp
1 year+17.7%+14.0%-3.7 pp
3-year CAGR+9.5%+11.1%+1.5 pp
5-year CAGR+9.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
365.34M USD
Year-over-year change
+17.7%
4-year CAGR
+6.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 selling, general & admin of $359.09M is the 3rd highest of the 10 companies compared; the peer median is $235.6M.
  • Its year-over-year change of +0.6% is the 7th highest of 10, against a peer median of +12.9%.
  • Selling, general & admin amounts to 46.9% of revenue for NEO, versus a peer median of 69.4%.
NEO Competitors Peer median
Selling, General & Admin for NEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$951.07M +44.5%+15.0%74.4%
MYGNMyriad Genetics, Inc.LTM Mar 2026$537.7M -3.2%+1.5%64.9%
NEONeoGenomics, Inc.LTM Jun 2026$359.09M +0.6%+9.5%46.9%
WGSGeneDx Holdings Corp.LTM Jun 2026$292.26M +58.0%-10.9%64.3%
GRALGRAIL, Inc.LTM Jun 2026$291.09M -3.7%-2.4%176.1%
CSTLCastle Biosciences, Inc.LTM Mar 2026$235.6M +12.1%+17.0%69.3%
VCYTVeracyte, Inc.LTM Jun 2026$201.58M -7.5%+6.6%35.9%
BDSXBiodesix, Inc.LTM Mar 2026$91.36M +13.7%+12.5%95.1%
PSNLPersonalis, Inc.LTM Mar 2026$59.21M +26.4%-5.7%91.8%
XGNExagen Inc.LTM Mar 2026$47.48M +12.9%-3.6%69.4%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $235.6M+12.9%+1.5%69.4%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.33M509.73M591.64M660.57M727.33M
Cost of Revenue297.27M321.83M347.04M370.47M444.79M
Gross Profit187.06M187.9M244.6M290.1M282.54M
Gross Margin38.6%36.9%41.3%43.9%38.8%
Research & Development21.87M30.33M27.31M31.16M37.08M
Selling, General & Admin283.94M277.91M279.96M310.49M365.34M
Operating Expenses305.81M345.52M352.34M382.21M348.62M
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
EBITDA46.5M(82.33M)(17.61M)(1.51M)(38.69M)
EBITDA Margin9.6%-16.2%-3.0%-0.2%-5.3%
Operating Income(118.75M)(157.62M)(107.74M)(92.11M)(66.08M)
Operating Margin-24.5%-30.9%-18.2%-13.9%-9.1%
Interest Income3.14M6.08M16.9M18.43M9.07M
Interest Expense8.22M7.58M6.91M6.62M3.75M
Other Income / Expenses103.68M(1.72M)10.64M11.43M(44.19M)
Income Before Tax(15.08M)(159.34M)(97.1M)(80.68M)(110.27M)
Pre-Tax Margin-3.1%-31.3%-16.4%-12.2%-15.2%
Income Tax Expense(6.73M)(15.09M)(9.13M)(1.95M)(2.24M)
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Net Margin-1.7%-28.3%-14.9%-11.9%-14.9%
EPS (Basic)(0.07)(1.16)(0.70)(0.62)(0.84)
EPS (Diluted)(0.07)(1.16)(0.70)(0.62)(0.84)
Weighted Avg Shares119.96M124.22M125.5M126.66M128.1M
Weighted Avg Shares (Diluted)119.96M124.22M125.5M126.66M128.1M

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.